---
document_datetime: 2025-12-02 04:53:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/exforge-hct.html
document_name: exforge-hct.html
version: success
processing_time: 0.157194
conversion_datetime: 2025-12-28 02:44:45.259309
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Exforge HCT

[RSS](/en/individual-human-medicine.xml/66094)

##### Authorised

This medicine is authorised for use in the European Union

amlodipine besilate / valsartan / hydrochlorothiazide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Exforge HCT](#news-on)
- [Related information on Exforge HCT](#related-information-on-exforge-hct-613)
- [More information on Exforge HCT](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Exforge HCT. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge HCT.

Expand section

Collapse section

## What is Exforge HCT?

Exforge HCT is a medicine that contains three active substances, amlodipine, valsartan and hydrochlorothiazide. It is available as tablets containing amlodipine, valsartan and hydrochlorothiazide in the following amounts: 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg, 10/160/25 mg and 10/320/25 mg.

## What is Exforge HCT used for?

Exforge HCT is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of amlodipine, valsartan and hydrochlorothiazide. 'Essential' means that the hypertension has no obvious cause.

The medicine can only be obtained with a prescription.

## How is Exforge HCT used?

Exforge HCT is taken by mouth as one tablet once a day, at the same time of the day and preferably in the morning. The dose of Exforge HCT to be used is the same as the doses of three individual active substances that the patient was taking before. The daily dose of Exforge HCT should not exceed 10 mg of amlodipine, 320 mg of valsartan and 25 mg of hydrochlorothiazide.

## How does Exforge HCT work?

The three active substances in Exforge HCT are anti-hypertensive medicines that are already in use in the European Union (EU).

Amlodipine is a 'calcium channel blocker'. It blocks special channels on the surface of cells called calcium channels, through which calcium ions normally enter the cells. When calcium ions enter the cells in the muscles of blood vessel walls, this causes contraction. By reducing the flow of calcium into the cells, amlodipine prevents the cells from contracting and helps the blood vessel walls to relax and widen, thereby reducing blood pressure.

Valsartan is an 'angiotensin II receptor antagonist', which means that it blocks the action of a body hormone called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone having an effect, allowing the blood vessels to widen and blood pressure to reduce.

Hydrochlorothiazide is a diuretic. It works by increasing urine output, reducing the volume of fluid in the blood and lowering the blood pressure.

The combination of the three active substances has an additive effect, reducing the blood pressure more than the individual medicines alone. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.

## How has Exforge HCT been studied?

Because the combination of the three active substances has been in use for a number of years, the company presented studies showing that the tablet containing all three substances is absorbed in the body in the same way as the separate tablets.

In addition, one main study was carried out in 2,271 patients with moderate to severe hypertension with the highest strength of Exforge HCT (320 mg valsartan, 10 mg amlodipine and 25 mg hydrochlorothiazide). Patients received either Exforge HCT or one of the three combinations containing only two of the active substances for eight weeks. The main measure of effectiveness was the average change in the blood pressure.

## What benefit has Exforge HCT shown during the studies?

Treatment with the highest strength of Exforge HCT was more effective at treating hypertension than dual combinations containing any of the two active substances. The average reduction in blood pressure was around 39.7/24.7 mmHg in patients taking Exforge HCT compared with 32/19.7 mmHg, 33.5/21.5 mmHg and 31.5/19.5 mmHg in patients taking valsartan/hydrochlorothiazide, valsartan/amlodipine and hydrochlorothiazide/amlodipine combinations, respectively.

## What is the risk associated with Exforge HCT?

The most common side effects with Exforge HCT (seen in between 1 and 10 patients in 100) are hypokalaemia (low blood potassium levels), dizziness, headache, hypotension (low blood pressure), dyspepsia (heartburn), pollakiuria (abnormally frequent urination), fatigue (tiredness) and oedema (fluid retention). For the full list of all side effects reported with Exforge HCT, see the package leaflet.

Exforge HCT must not be used in people who are hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Exforge HCT. It must not be used in women who are more than three months pregnant. It must also not be used in patients who have liver or bile problems (such as jaundice), severe kidney problems, anuria (a condition in which a patient cannot make or pass urine) or in patients undergoing dialysis (a blood clearance technique). Finally, Exforge HCT must not be used in patients with hypokalaemia (low blood potassium levels), hyponatraemia (low blood sodium levels) and hypercalcaemia (high blood calcium levels) that do not respond to treatment and in patients with hyperuricaemia (high blood levels of uric acid) that causes symptoms.

Exforge HCT must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.

## Why has Exforge HCT been approved?

The CHMP noted that patients already taking the three active substances would be more likely to comply with their treatment if prescribed Exforge HCT which combines the three substances in a single tablet. The main study showed the benefit of the highest strength of Exforge HCT in lowering the blood pressure. For all doses, Exforge HCT also met requirements to prove that it was comparable to the combinations of the individual active substances taken separately. The CHMP therefore decided that Exforge HCT's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Exforge HCT:

The European Commission granted a marketing authorisation valid throughout the European Union for Exforge HCT on 16 October 2009.

For more information about treatment with Exforge HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Exforge HCT : EPAR - Summary for the public

English (EN) (75.96 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 12/12/2013

[View](/en/documents/overview/exforge-hct-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-850)

български (BG) (104.42 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/bg/documents/overview/exforge-hct-epar-summary-public_bg.pdf)

español (ES) (77.18 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/es/documents/overview/exforge-hct-epar-summary-public_es.pdf)

čeština (CS) (103.98 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/cs/documents/overview/exforge-hct-epar-summary-public_cs.pdf)

dansk (DA) (98.5 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/da/documents/overview/exforge-hct-epar-summary-public_da.pdf)

Deutsch (DE) (100.13 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/de/documents/overview/exforge-hct-epar-summary-public_de.pdf)

eesti keel (ET) (75.95 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/et/documents/overview/exforge-hct-epar-summary-public_et.pdf)

ελληνικά (EL) (143.05 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/el/documents/overview/exforge-hct-epar-summary-public_el.pdf)

français (FR) (107 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/fr/documents/overview/exforge-hct-epar-summary-public_fr.pdf)

hrvatski (HR) (93.85 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/hr/documents/overview/exforge-hct-epar-summary-public_hr.pdf)

italiano (IT) (98.52 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/it/documents/overview/exforge-hct-epar-summary-public_it.pdf)

latviešu valoda (LV) (121.36 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/lv/documents/overview/exforge-hct-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (99.74 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/lt/documents/overview/exforge-hct-epar-summary-public_lt.pdf)

magyar (HU) (97.7 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/hu/documents/overview/exforge-hct-epar-summary-public_hu.pdf)

Malti (MT) (125.76 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/mt/documents/overview/exforge-hct-epar-summary-public_mt.pdf)

Nederlands (NL) (76.6 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/nl/documents/overview/exforge-hct-epar-summary-public_nl.pdf)

polski (PL) (104.1 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/pl/documents/overview/exforge-hct-epar-summary-public_pl.pdf)

português (PT) (76.61 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/pt/documents/overview/exforge-hct-epar-summary-public_pt.pdf)

română (RO) (122.15 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/ro/documents/overview/exforge-hct-epar-summary-public_ro.pdf)

slovenčina (SK) (124.16 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/sk/documents/overview/exforge-hct-epar-summary-public_sk.pdf)

slovenščina (SL) (93.68 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/sl/documents/overview/exforge-hct-epar-summary-public_sl.pdf)

Suomi (FI) (98.51 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/fi/documents/overview/exforge-hct-epar-summary-public_fi.pdf)

svenska (SV) (77.26 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/12/2013

[View](/sv/documents/overview/exforge-hct-epar-summary-public_sv.pdf)

## Product information

Exforge HCT : EPAR - Product Information

English (EN) (489.2 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 12/02/2025

[View](/en/documents/product-information/exforge-hct-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-695)

български (BG) (693.41 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/bg/documents/product-information/exforge-hct-epar-product-information_bg.pdf)

español (ES) (576.15 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/es/documents/product-information/exforge-hct-epar-product-information_es.pdf)

čeština (CS) (557.89 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/cs/documents/product-information/exforge-hct-epar-product-information_cs.pdf)

dansk (DA) (534.36 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/da/documents/product-information/exforge-hct-epar-product-information_da.pdf)

Deutsch (DE) (468.45 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/de/documents/product-information/exforge-hct-epar-product-information_de.pdf)

eesti keel (ET) (504.02 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/et/documents/product-information/exforge-hct-epar-product-information_et.pdf)

ελληνικά (EL) (619.45 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/el/documents/product-information/exforge-hct-epar-product-information_el.pdf)

français (FR) (659.05 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/fr/documents/product-information/exforge-hct-epar-product-information_fr.pdf)

hrvatski (HR) (621.22 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/hr/documents/product-information/exforge-hct-epar-product-information_hr.pdf)

íslenska (IS) (508.86 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/is/documents/product-information/exforge-hct-epar-product-information_is.pdf)

italiano (IT) (531.87 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/it/documents/product-information/exforge-hct-epar-product-information_it.pdf)

latviešu valoda (LV) (630.53 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/lv/documents/product-information/exforge-hct-epar-product-information_lv.pdf)

lietuvių kalba (LT) (644.36 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/lt/documents/product-information/exforge-hct-epar-product-information_lt.pdf)

magyar (HU) (564.42 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/hu/documents/product-information/exforge-hct-epar-product-information_hu.pdf)

Malti (MT) (716.17 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/mt/documents/product-information/exforge-hct-epar-product-information_mt.pdf)

Nederlands (NL) (505.21 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/nl/documents/product-information/exforge-hct-epar-product-information_nl.pdf)

norsk (NO) (586.46 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/no/documents/product-information/exforge-hct-epar-product-information_no.pdf)

polski (PL) (700.72 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/pl/documents/product-information/exforge-hct-epar-product-information_pl.pdf)

português (PT) (617.06 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/pt/documents/product-information/exforge-hct-epar-product-information_pt.pdf)

română (RO) (557.84 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/ro/documents/product-information/exforge-hct-epar-product-information_ro.pdf)

slovenčina (SK) (673.59 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/sk/documents/product-information/exforge-hct-epar-product-information_sk.pdf)

slovenščina (SL) (541.3 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/sl/documents/product-information/exforge-hct-epar-product-information_sl.pdf)

Suomi (FI) (507.47 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/fi/documents/product-information/exforge-hct-epar-product-information_fi.pdf)

svenska (SV) (575.11 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/02/2025

[View](/sv/documents/product-information/exforge-hct-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000246587 11/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Exforge HCT : EPAR - All Authorised presentations

English (EN) (20.81 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 12/11/2009

[View](/en/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-174)

български (BG) (90.38 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/bg/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_bg.pdf)

español (ES) (22.94 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/es/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_es.pdf)

čeština (CS) (88.52 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/cs/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (23.22 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/da/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (23.12 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/de/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (24.01 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/et/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (89.24 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/el/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_el.pdf)

français (FR) (23.84 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/fr/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (65.67 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/hr/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (42.6 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/is/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_is.pdf)

italiano (IT) (22.96 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/it/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (91.05 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/lv/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (91.51 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/lt/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (93.07 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/hu/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (87.61 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/mt/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.03 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/nl/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (46.54 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/no/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.41 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/pl/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.71 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/pt/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_pt.pdf)

română (RO) (87.55 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/ro/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (86.4 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/sk/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (21.79 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/sl/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/fi/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (21.35 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/sv/documents/all-authorised-presentations/exforge-hct-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Exforge HCT Active substance

- valsartan
- hydrochlorothiazide
- amlodipine besilate

International non-proprietary name (INN) or common name

- amlodipine besilate
- valsartan
- hydrochlorothiazide

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09DX01

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

## Authorisation details

EMA product number EMEA/H/C/001068 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 15/10/2009 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Exforge HCT : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.3 KB - PDF)

**First published:** 12/02/2025

[View](/en/documents/procedural-steps-after/exforge-hct-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Exforge HCT : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (6.39 MB - PDF)

**First published:** 26/08/2010

**Last updated:** 12/02/2025

[View](/en/documents/procedural-steps-after/exforge-hct-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

English (EN) (119.28 KB - PDF)

**First published:** 05/07/2021

[View](/en/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

[Other languages (22)](#file-language-dropdown-233)

български (BG) (145.18 KB - PDF)

**First published:**

05/07/2021

[View](/bg/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_bg.pdf)

español (ES) (125.85 KB - PDF)

**First published:**

05/07/2021

[View](/es/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_es.pdf)

čeština (CS) (139.02 KB - PDF)

**First published:**

05/07/2021

[View](/cs/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_cs.pdf)

dansk (DA) (126.81 KB - PDF)

**First published:**

05/07/2021

[View](/da/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_da.pdf)

Deutsch (DE) (131.05 KB - PDF)

**First published:**

05/07/2021

[View](/de/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_de.pdf)

eesti keel (ET) (123.85 KB - PDF)

**First published:**

05/07/2021

[View](/et/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_et.pdf)

ελληνικά (EL) (139.5 KB - PDF)

**First published:**

05/07/2021

[View](/el/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_el.pdf)

français (FR) (127.12 KB - PDF)

**First published:**

05/07/2021

[View](/fr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fr.pdf)

hrvatski (HR) (142.87 KB - PDF)

**First published:**

05/07/2021

[View](/hr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hr.pdf)

italiano (IT) (126.56 KB - PDF)

**First published:**

05/07/2021

[View](/it/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_it.pdf)

latviešu valoda (LV) (147.7 KB - PDF)

**First published:**

05/07/2021

[View](/lv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lv.pdf)

lietuvių kalba (LT) (148.34 KB - PDF)

**First published:**

05/07/2021

[View](/lt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lt.pdf)

magyar (HU) (137.17 KB - PDF)

**First published:**

05/07/2021

[View](/hu/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hu.pdf)

Malti (MT) (151.21 KB - PDF)

**First published:**

05/07/2021

[View](/mt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_mt.pdf)

Nederlands (NL) (127.53 KB - PDF)

**First published:**

05/07/2021

[View](/nl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_nl.pdf)

polski (PL) (137.7 KB - PDF)

**First published:**

05/07/2021

[View](/pl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pl.pdf)

português (PT) (128.87 KB - PDF)

**First published:**

05/07/2021

[View](/pt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pt.pdf)

română (RO) (143.59 KB - PDF)

**First published:**

05/07/2021

[View](/ro/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_ro.pdf)

slovenčina (SK) (135.07 KB - PDF)

**First published:**

05/07/2021

[View](/sk/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sk.pdf)

slovenščina (SL) (149.74 KB - PDF)

**First published:**

05/07/2021

[View](/sl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sl.pdf)

Suomi (FI) (125.84 KB - PDF)

**First published:**

05/07/2021

[View](/fi/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fi.pdf)

svenska (SV) (126.99 KB - PDF)

**First published:**

05/07/2021

[View](/sv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

Reference Number: EMA/47245/2021

English (EN) (362.31 KB - PDF)

**First published:** 02/03/2021

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

Exforge HCT : EPAR - Scientific conclusions - Annex IV

English (EN) (99.42 KB - PDF)

**First published:** 16/08/2019

[View](/en/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_en.pdf)

[Other languages (22)](#file-language-dropdown-300)

български (BG) (136.15 KB - PDF)

**First published:**

16/08/2019

[View](/bg/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_bg.pdf)

español (ES) (98.31 KB - PDF)

**First published:**

16/08/2019

[View](/es/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_es.pdf)

čeština (CS) (131.08 KB - PDF)

**First published:**

16/08/2019

[View](/cs/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_cs.pdf)

dansk (DA) (96.12 KB - PDF)

**First published:**

16/08/2019

[View](/da/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_da.pdf)

Deutsch (DE) (100.2 KB - PDF)

**First published:**

16/08/2019

[View](/de/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_de.pdf)

eesti keel (ET) (94.4 KB - PDF)

**First published:**

16/08/2019

[View](/et/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_et.pdf)

ελληνικά (EL) (142.79 KB - PDF)

**First published:**

16/08/2019

[View](/el/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_el.pdf)

français (FR) (97.56 KB - PDF)

**First published:**

16/08/2019

[View](/fr/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_fr.pdf)

hrvatski (HR) (125.02 KB - PDF)

**First published:**

16/08/2019

[View](/hr/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

16/08/2019

[View](/it/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_it.pdf)

latviešu valoda (LV) (130.68 KB - PDF)

**First published:**

16/08/2019

[View](/lv/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_lv.pdf)

lietuvių kalba (LT) (130.84 KB - PDF)

**First published:**

16/08/2019

[View](/lt/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_lt.pdf)

magyar (HU) (119.82 KB - PDF)

**First published:**

16/08/2019

[View](/hu/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_hu.pdf)

Malti (MT) (133.78 KB - PDF)

**First published:**

16/08/2019

[View](/mt/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_mt.pdf)

Nederlands (NL) (99.3 KB - PDF)

**First published:**

16/08/2019

[View](/nl/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

16/08/2019

[View](/pl/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

16/08/2019

[View](/pt/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_pt.pdf)

română (RO) (128.25 KB - PDF)

**First published:**

16/08/2019

[View](/ro/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_ro.pdf)

slovenčina (SK) (119.14 KB - PDF)

**First published:**

16/08/2019

[View](/sk/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_sk.pdf)

slovenščina (SL) (124.14 KB - PDF)

**First published:**

16/08/2019

[View](/sl/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_sl.pdf)

Suomi (FI) (97.12 KB - PDF)

**First published:**

16/08/2019

[View](/fi/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_fi.pdf)

svenska (SV) (96.85 KB - PDF)

**First published:**

16/08/2019

[View](/sv/documents/scientific-conclusion/exforge-hct-epar-scientific-conclusions-annex-iv_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report

Adopted

Reference Number: EMA/217823/2019

English (EN) (531.32 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf)

Exforge HCT-H-C-1068-A31-0029 : EPAR - Assessment Report - Article 31

Adopted

English (EN) (301.42 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/variation-report/exforge-hct-h-c-1068-a31-0029-epar-assessment-report-article-31_en.pdf)

Exforge HCT-H-C-1068-A31-0029 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recom...

English (EN) (48.81 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_en.pdf)

[Other languages (22)](#file-language-dropdown-597)

български (BG) (87.49 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/bg/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/es/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/cs/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/da/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/de/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/et/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/el/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fr/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hr/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/it/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lv/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lt/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hu/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/mt/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/nl/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pl/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pt/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/ro/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sk/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sl/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fi/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sv/documents/scientific-conclusion/exforge-hct-h-c-1068-a31-0029-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recom_sv.pdf)

Exforge HCT-H-C-1068-WS-0359 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/356309/2013

English (EN) (446.67 KB - PDF)

**First published:** 12/12/2013

**Last updated:** 12/12/2013

[View](/en/documents/variation-report/exforge-hct-h-c-1068-ws-0359-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Exforge HCT

Adopted

Reference Number: EMA/CHMP/388293/2013

English (EN) (68.44 KB - PDF)

**First published:** 28/06/2013

**Last updated:** 28/06/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-exforge-hct_en.pdf)

## Initial marketing authorisation documents

Exforge HCT : EPAR - Public assessment report

English (EN) (1.23 MB - PDF)

**First published:** 12/11/2009

**Last updated:** 12/11/2009

[View](/en/documents/assessment-report/exforge-hct-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use summary of positive opinion for Exforge HCT

Reference Number: EMEA/CHMP/450701/2009

English (EN) (34.3 KB - PDF)

**First published:** 23/07/2009

**Last updated:** 23/07/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-exforge-hct_en.pdf)

#### News on Exforge HCT

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2013) 28/06/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

#### Related information on Exforge HCT

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

#### More information on Exforge HCT

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)
- [Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - referral](/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 12/02/2025

## Share this page

[Back to top](#main-content)